• Relative Versus Fractional Viability in Cancer Models

  2026-08-20

  Hannah R. Schwartz’s dissertation distinguishes relative viability, which combines growth inhibition and cell loss, from fractional viability, which more specifically reflects drug-induced killing. This framework improves interpretation of in vitro anticancer responses by preserving both response magnitude and timing, helping researchers separate cytostatic effects from cytotoxic effects.

• Gastric Cancer Assembloids and Stromal Drug Response

  2026-08-20

  Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid model that combines matched tumor organoids with tumor-derived stromal subpopulations. The model reproduced broader tumor–microenvironment signaling than monocultures and revealed that stromal composition can alter drug sensitivity, providing a more informative platform for resistance studies and personalized treatment design.

• 10074-G5: A c-Myc Inhibitor for Cancer Research

  2026-08-19

  10074-G5 is a small-molecule c-Myc inhibitor that disrupts c-Myc/Max dimerization. Product data report micromolar activity in Daudi and HL-60 cells and tumor-growth suppression in a Daudi xenograft model, while mechanistic evidence connects c-MYC signaling with aggressive esophageal adenocarcinoma phenotypes.

• SR-202 PPARγ Antagonist Workflows

  2026-08-19

  SR-202 enables mechanism-first experiments that connect PPARγ activity with macrophage polarization, adipocyte differentiation, and metabolic phenotypes. This practical guide translates the reference study into cell-based workflows, assay controls, and troubleshooting strategies for insulin resistance research, obesity research, and inflammatory models.

• ML365: From TASK1 Inhibition to Translational Insight

  2026-08-18

  ML365 is more than a potent TASK1 channel probe: it offers a framework for connecting membrane-potential biology with hippocampal inflammation. This article examines the 2024 Brain Research evidence linking ML365 to reduced postoperative cognitive impairment, explains the assay and selectivity considerations that shape interpretation, and outlines a translational strategy for ion channel pharmacology research.

• Fluo-4 AM for Calcium Signaling Research

  2026-08-18

  Fluo-4 AM is a cell-permeant fluorescent calcium indicator for real-time intracellular calcium concentration measurement. Its ester-cleavable design converts intracellular Ca2+ changes into fluorescence-intensity changes, supporting calcium signaling assays while requiring assay-specific controls and calibration.

• Vacuolin-1 Workflow for Lysosomal Exocytosis

  2026-08-17

  Vacuolin-1 provides a selective way to separate calcium-triggered lysosome-plasma membrane fusion from broader trafficking or secretion changes. This guide translates recent MPS IVA cartilage findings into practical β-hexosaminidase, LAMP1, membrane-repair, and signaling workflows.

• T. pallidum, Mitochondrial ROS, and Hepatocyte Apoptosis

  2026-08-17

  The reference study identifies mitochondrial reactive oxygen species accumulation and cardiolipin peroxidation as central events in Treponema pallidum-induced intrinsic apoptosis in hepatocytes. Its integrated analysis of mitochondrial function, pore opening, oxidative injury, and apoptotic signaling provides a framework for mitochondrial permeability transition pore detection and related cell death mechanism research.

• TSPAN18-STIM1 Signaling in Prostate Cancer Bone Metastasis

  2026-08-16

  Zhou et al. identify TSPAN18 as a regulator of STIM1 stability, showing that it prevents TRIM32-mediated ubiquitination and sustains store-operated calcium entry in prostate cancer cells. The study connects this molecular mechanism to migration, invasion, bone metastasis, and adverse clinical features, providing a framework for investigating the STIM1-Ca2+ signaling axis as a therapeutic vulnerability.

• p-Cresyl Sulfate and Aortic Valve Calcification

  2026-08-15

  The reference study identifies p-cresyl sulfate as a mechanistic driver of calcification in porcine aortic valvular interstitial cells, linking HIF-1α activation and klotho/SIRT1 disruption to NF-κB and RUNX2 signaling. Its cell and rat CKD experiments suggest that klotho and SIRT1 activation may be useful experimental strategies for investigating uremia-associated calcific aortic valve disease, while stopping short of establishing a clinical treatment.

• Amiloride (MK-870) Workflows for Ion Transport

  2026-08-14

  Amiloride (MK-870) helps researchers separate epithelial sodium flux from uPAR-associated uptake and signaling. This practical guide connects dose-controlled inhibition, endocytosis assays, and nanovaccine mechanism studies while emphasizing controls that prevent off-target interpretation.

• Sumatriptan B4981 for Reliable Cell Assays

  2026-08-14

  This scenario-driven guide explains how Sumatriptan, SKU B4981, can be integrated into cell viability, proliferation, cytotoxicity, and inflammation workflows without confusing receptor-mediated effects with nonspecific toxicity. It combines product parameters, concentration guidance, assay controls, and translational evidence to support more reproducible experimental decisions.

• Ionomycin Calcium Salt: Calcium Signaling Guide

  2026-08-13

  Ionomycin calcium salt is a calcium ionophore that raises intracellular Ca2+ by mobilizing cellular stores and promoting extracellular influx. Product-dossier evidence supports its use in calcium signaling studies, secretion assays, muscle protein regulation, and model-specific cancer research, while the prostate cancer literature provides a distinct framework for interpreting Ca2+-dependent signaling.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-08-13

  Borchert et al. linked homologous recombination repair defects, or BRCAness, with olaparib sensitivity in malignant pleural mesothelioma models. Their integrated cell-line and patient-sample analysis highlights BAP1-associated vulnerability, combination effects with cisplatin, and gene-expression markers that may support biomarker-guided PARP inhibition.

• D-Lin-MC3-DMA in Reliable RNA Assays

  2026-08-12

  Learn how D-Lin-MC3-DMA (SKU A8791) can support controlled siRNA and mRNA lipid nanoparticle workflows when viability, transfection, and cytotoxicity readouts are difficult to reconcile. This practical guide connects ionizable-lipid chemistry, formulation handling, assay controls, and evidence from a 216-formulation mRNA study.

532 records 6/36 page Previous Next First page 上5页 678910 下5页 Last page